Cytek Biosciences (CTKB) Cash & Equivalents (2020 - 2026)

Cytek Biosciences has reported Cash & Equivalents for 7 years, with the latest figure at $65.7 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 31.06% year-over-year to $65.7 million; the trailing twelve-month figure through Mar 2026 stood at $65.7 million (down 31.06% YoY), and the FY2025 full-year result was $90.9 million, down 7.97% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $65.7 million, down from $90.9 million in the prior quarter.
• The five-year high for Cash & Equivalents was $349.9 million in Q2 2022, with the low at $65.7 million in Q1 2026.
• Historically, Cash & Equivalents has averaged $173.7 million across 5 years, with a median of $162.3 million in 2024.
• Annual changes were most pronounced in 2022 — Cash & Equivalents soared 118.9% — and 2023, when it tumbled 62.41%.
• Cytek Biosciences' Cash & Equivalents stood at $296.6 million in 2022, then sank by 43.59% to $167.3 million in 2023, then slumped by 40.99% to $98.7 million in 2024, then fell by 7.97% to $90.9 million in 2025, then fell by 27.69% to $65.7 million in 2026.
• The last three Cash & Equivalents figures came in at $65.7 million (Q1 2026), $90.9 million (Q4 2025), and $93.3 million (Q3 2025), per Business Quant data.